from the United States Court of Appeals for the Federal Circuit
See other cases from the Federal Circuit.
The Solicitor General is invited to file a brief in this case expressing the views of the United States.
Reply of petitioner Teva Pharmaceuticals USA, Inc. filed. (Distributed)
Brief of respondents GlaxoSmithKline LLC, et al. in opposition filed.
Brief amicus curiae of Association for Accessible Medicines filed.
Brief amicus curiae of Mylan Pharmaceuticals Inc. filed.
Brief amicus curiae of Alvotech filed.
Brief amici curiae of 42 Professors of Law, Economics, Business, and Medicine filed.
Petition for a writ of certiorari filed. (Response due August 12, 2022)
Application (21A677) granted by The Chief Justice extending the time to file until July 11, 2022.
Application (21A677) to extend the time to file a petition for a writ of certiorari from May 12, 2022 to July 11, 2022, submitted to The Chief Justice.
Teva Pharmaceuticals USA, Inc., Petitioner, represented by William McGinley Jay
GlaxoSmithKline LLC, et al., Respondent, represented by Juanita R. Brooks
42 Professors of Law, Economics, Business, and Medicine, Amicus Curiae, represented by Charles Duan
Alvotech, Amicus Curiae, represented by Jonathan Yates Ellis
Association for Accessible Medicines, Amicus Curiae, represented by Matthew S. Hellman
Mylan Pharmaceuticals Inc., Amicus Curiae, represented by Steffen Nathanael Johnson